Flare Therapeutics Announces Strategic Discovery Collaboration With Roche, Potentially Exceeding $1.8 Billion

New York – November 20, 2024 – Cooley advised Flare Therapeutics on its strategic discovery collaboration with Roche. Under the collaboration, the company will receive a $70 million upfront cash payment and will be eligible to receive discovery, development and commercialization milestone payments potentially exceeding $1.8 billion, plus royalties. Flare Therapeutics, a clinical-stage biotechnology company targeting transcription factors to discover precision medicines for oncology and other therapeutic areas, will lead discovery and preclinical activities targeting multiple transcription factor targets in oncology, while Roche will leverage its industry-leading capabilities in oncology to pursue the further preclinical and clinical development and commercialization of the collaboration’s potential products.

Lawyers Kate Hillier and Christophe Beauduin led the Cooley team advising Flare Therapeutics.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has more than 1,300 lawyers across 19 offices in the United States, Asia and Europe, and a total workforce of nearly 3,000.

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.